Denosumab治疗不可切除的骨巨细胞瘤停药后进展如何?

IF 1.5 Q4 ONCOLOGY Cancer reports Pub Date : 2025-01-11 DOI:10.1002/cnr2.70117
DENO Research Group, Carolina de la Calva, Manuel Angulo, Paula González-Rojo, Ana Peiró, Pau Machado, Juan Luis Cebrián, Roberto García-Maroto, Antonio Valcárcel, Pablo Puertas, Gregorio Valero-Cifuentes, Óscar Pablos, Miriam Maireles, María Luisa Fontalva, Iván Chaves, Aida Orce, Luis Coll-Mesa, Israel Pérez, Fausto González, María del Carmen Sanz, Isidro Gracia
{"title":"Denosumab治疗不可切除的骨巨细胞瘤停药后进展如何?","authors":"DENO Research Group,&nbsp;Carolina de la Calva,&nbsp;Manuel Angulo,&nbsp;Paula González-Rojo,&nbsp;Ana Peiró,&nbsp;Pau Machado,&nbsp;Juan Luis Cebrián,&nbsp;Roberto García-Maroto,&nbsp;Antonio Valcárcel,&nbsp;Pablo Puertas,&nbsp;Gregorio Valero-Cifuentes,&nbsp;Óscar Pablos,&nbsp;Miriam Maireles,&nbsp;María Luisa Fontalva,&nbsp;Iván Chaves,&nbsp;Aida Orce,&nbsp;Luis Coll-Mesa,&nbsp;Israel Pérez,&nbsp;Fausto González,&nbsp;María del Carmen Sanz,&nbsp;Isidro Gracia","doi":"10.1002/cnr2.70117","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Denosumab represents a valuable treatment option for unresectable giant cell tumors of the bone (GCTBs). However, no standardized protocols exist determining the length of administration, with few studies having been published on patients who reached the end of treatment.</p>\n </section>\n \n <section>\n \n <h3> Aims</h3>\n \n <p>To analyze the outcomes of patients diagnosed with GCTB and who had finished single treatment with denosumab.</p>\n </section>\n \n <section>\n \n <h3> Methods and Results</h3>\n \n <p>This is a multicenter, retrospective, descriptive study carried out in seven Spanish hospitals with multidisciplinary sarcoma and musculoskeletal tumor boards, between 2009 and 2019. Sixteen patients diagnosed with unresectable GCTBs and treated with denosumab who had reached the end of their treatment were recruited for the study and had been followed up for a minimum of 2 years. Fifty percent of patients discontinued denosumab after showing signs of tumor control. The disease remained stable in 69% of patients (<i>n</i> = 11), with a median recurrence-free survival time of 46 months (20–157 months) after being treated for a median period of 19 months (5–83 months). Four patients experienced local progression, and one presented multifocal progression. These five patients were treated for a median period of 46 months (14–76 months), with a median recurrence-free survival time of 9 months (5–25 months).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The findings of the present study suggest that discontinuation of denosumab in patients with unresectable GCTB is not necessarily associated with the progression of the disease. Further research is needed to determine how long denosumab should be administered to minimize the risk of recurrence.</p>\n </section>\n </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 1","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11726647/pdf/","citationCount":"0","resultStr":"{\"title\":\"Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment?\",\"authors\":\"DENO Research Group,&nbsp;Carolina de la Calva,&nbsp;Manuel Angulo,&nbsp;Paula González-Rojo,&nbsp;Ana Peiró,&nbsp;Pau Machado,&nbsp;Juan Luis Cebrián,&nbsp;Roberto García-Maroto,&nbsp;Antonio Valcárcel,&nbsp;Pablo Puertas,&nbsp;Gregorio Valero-Cifuentes,&nbsp;Óscar Pablos,&nbsp;Miriam Maireles,&nbsp;María Luisa Fontalva,&nbsp;Iván Chaves,&nbsp;Aida Orce,&nbsp;Luis Coll-Mesa,&nbsp;Israel Pérez,&nbsp;Fausto González,&nbsp;María del Carmen Sanz,&nbsp;Isidro Gracia\",\"doi\":\"10.1002/cnr2.70117\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Denosumab represents a valuable treatment option for unresectable giant cell tumors of the bone (GCTBs). However, no standardized protocols exist determining the length of administration, with few studies having been published on patients who reached the end of treatment.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Aims</h3>\\n \\n <p>To analyze the outcomes of patients diagnosed with GCTB and who had finished single treatment with denosumab.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods and Results</h3>\\n \\n <p>This is a multicenter, retrospective, descriptive study carried out in seven Spanish hospitals with multidisciplinary sarcoma and musculoskeletal tumor boards, between 2009 and 2019. Sixteen patients diagnosed with unresectable GCTBs and treated with denosumab who had reached the end of their treatment were recruited for the study and had been followed up for a minimum of 2 years. Fifty percent of patients discontinued denosumab after showing signs of tumor control. The disease remained stable in 69% of patients (<i>n</i> = 11), with a median recurrence-free survival time of 46 months (20–157 months) after being treated for a median period of 19 months (5–83 months). Four patients experienced local progression, and one presented multifocal progression. These five patients were treated for a median period of 46 months (14–76 months), with a median recurrence-free survival time of 9 months (5–25 months).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>The findings of the present study suggest that discontinuation of denosumab in patients with unresectable GCTB is not necessarily associated with the progression of the disease. Further research is needed to determine how long denosumab should be administered to minimize the risk of recurrence.</p>\\n </section>\\n </div>\",\"PeriodicalId\":9440,\"journal\":{\"name\":\"Cancer reports\",\"volume\":\"8 1\",\"pages\":\"\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-01-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11726647/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.70117\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.70117","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:Denosumab对于不可切除的骨巨细胞瘤(GCTBs)是一种有价值的治疗选择。然而,目前还没有确定给药时间长短的标准方案,关于治疗结束的患者的研究也很少发表。目的:分析诊断为GCTB并完成denosumab单药治疗的患者的预后。方法和结果:这是一项多中心、回顾性、描述性研究,于2009年至2019年间在西班牙七家拥有多学科肉瘤和肌肉骨骼肿瘤委员会的医院进行。16名被诊断为不可切除的GCTBs并接受denosumab治疗的患者被招募参加研究,并进行了至少2年的随访。50%的患者在出现肿瘤控制的迹象后停止使用denosumab。69%的患者(n = 11)病情保持稳定,中位无复发生存期为46个月(20-157个月),治疗中位期为19个月(5-83个月)。4例患者出现局部进展,1例出现多灶进展。这5例患者的中位治疗期为46个月(14-76个月),中位无复发生存期为9个月(5-25个月)。结论:本研究的结果表明,不可切除的GCTB患者停用denosumab并不一定与疾病进展相关。需要进一步的研究来确定denosumab应该使用多长时间以最小化复发风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment?

Background

Denosumab represents a valuable treatment option for unresectable giant cell tumors of the bone (GCTBs). However, no standardized protocols exist determining the length of administration, with few studies having been published on patients who reached the end of treatment.

Aims

To analyze the outcomes of patients diagnosed with GCTB and who had finished single treatment with denosumab.

Methods and Results

This is a multicenter, retrospective, descriptive study carried out in seven Spanish hospitals with multidisciplinary sarcoma and musculoskeletal tumor boards, between 2009 and 2019. Sixteen patients diagnosed with unresectable GCTBs and treated with denosumab who had reached the end of their treatment were recruited for the study and had been followed up for a minimum of 2 years. Fifty percent of patients discontinued denosumab after showing signs of tumor control. The disease remained stable in 69% of patients (n = 11), with a median recurrence-free survival time of 46 months (20–157 months) after being treated for a median period of 19 months (5–83 months). Four patients experienced local progression, and one presented multifocal progression. These five patients were treated for a median period of 46 months (14–76 months), with a median recurrence-free survival time of 9 months (5–25 months).

Conclusion

The findings of the present study suggest that discontinuation of denosumab in patients with unresectable GCTB is not necessarily associated with the progression of the disease. Further research is needed to determine how long denosumab should be administered to minimize the risk of recurrence.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cancer reports
Cancer reports Medicine-Oncology
CiteScore
2.70
自引率
5.90%
发文量
160
审稿时长
17 weeks
期刊最新文献
Development of a Nomogram-Based Online Calculator for Predicting Cancer-Specific Survival in Patients With Digestive Tract Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms (MiNENs): An Analysis of the SEER Database Investigate of LOC101928988 Regulatory Effect on the DAPK2 Transcription in Breast Tumors A Case Series and Literature Review on Zanubrutinib Therapy for the Treatment of Relapsed/Refractory Immune Thrombocytopenia Mechanisms of GPM6A in Malignant Tumors Distribution, Risk Factors and Epidemiological Trends of Pancreatic Cancer Across Countries’ Income Levels: A Comprehensive Analysis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1